Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adams Revenue Grows 11% As Mucinex Sales Shift Toward Line Extensions

This article was originally published in The Tan Sheet

Executive Summary

Adams Respiratory Therapeutics' net sales grew 11 percent to $84 million in its latest quarter as sales of single-ingredient Mucinex were cannibalized by newer extensions in the product line

You may also be interested in...



Max Strength Mucinex Sales Could Reach $70M In Debut Season – Adams

Adams Respiratory Therapeutics projects sales of its forthcoming Maximum Strength Mucinex products will eventually make up 60 percent of total Mucinex sales, the firm said April 4

CBD Lotion Firm’s ‘FDA Certified’ Claim For 'OTC Drug' Is Certifiably Noncompliant

In addition to CBD, Elixicure is formulated with OTC external analgesics monograph ingredients camphor and menthol, But CBD isn't a monograph drug nor approved for use in any pharmaceutical product other than GW Pharmaceutical's Epidiolex.

FDA Budget Request Proposes OTC Monograph User Fees And ‘Field Alerts’

In addition proposing $28.4m in monograph user fees, agency’s FY 2021 budget justification includes among its legislative initiatives proposing to require "Field Alert Reports" for drug products not marketed under an approved application, such as monograph OTCs.

Topics

UsernamePublicRestriction

Register

PS100488

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel